Proceedings of the National Academy of Sciences, Volume 123, Issue 15, April 2026. SignificanceThe premise of these studies was to develop and validate a therapeutic for opioid use disorder. Using an AI-based platform aimed at polypharmacy-focused drug discovery, two compounds were synthesized and tested, GATC-021 and GATC-1021. We …

Read original article